Recent well-designed trials have demonstrated that targeted molecular therapies, including VEGF and m-TOR inhibitors, were proved to have equal effectiveness with cytokine-based treatment for advanced RCC, but without the related toxicity [74,86]. This evidence concerns the gene VEGFA and renal cell carcinoma.